SCHEMBL1844792

SCHEMBL1844792

CN1C(=O)Cc2cnc(N3CCCCC3)nc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TSHR P16473 2/20 0.43
ALDH1A1 P00352 6/20 0.40
MAPK1 P28482 2/20 0.40
USP2 O75604 3/20 0.39
CYP1A2 P05177 3/20 0.39
HSD17B10 Q99714 3/20 0.39
CASP1 P29466 3/20 0.39
CASP7 P55210 2/20 0.39
HRH4 Q9H3N8 2/20 0.38
HRH1 P35367 1/20 0.38
GBA1 P04062 1/20 0.38
HSP90AA1 P07900 2/20 0.36
KMT2A Q03164 2/20 0.36
MAPT P10636 1/20 0.36
HTR3A P46098 1/20 0.36
IDH1 O75874 1/20 0.35
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL194797 0.90 POLB (0.42) POLBSMN1; SMN2TSHRALDH1A1MAPK1
Maleic Acid SCHEMBL2882692 0.90 POLB (0.42) POLBSMN1; SMN2TSHRALDH1A1MAPK1
SCHEMBL1845477 0.90 ALDH1A1 (0.49) TSHRALDH1A1MAPK1USP2CYP1A2
SCHEMBL1847339 0.86 ALDH1A1 (0.48) SMN1; SMN2TSHRALDH1A1MAPK1USP2
SCHEMBL1848688 0.86 ALDH1A1 (0.37) TSHRALDH1A1MAPK1USP2CYP1A2
SCHEMBL1848137 0.86 KDM4E (0.51) POLBTSHRALDH1A1MAPK1USP2
SCHEMBL1845608 0.85 ALDH1A1 (0.38) POLBSMN1; SMN2TSHRALDH1A1MAPK1
SCHEMBL1846364 0.83 LMNA (0.42) TSHRALDH1A1MAPK1USP2CYP1A2
SCHEMBL1845316 0.82 POLB (0.39) POLBSMN1; SMN2TSHRALDH1A1MAPK1
SCHEMBL1848808 0.82 SMO (0.46) POLBSMN1; SMN2ALDH1A1USP2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2324023-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA (US) 2011-05-25 EP claimed
WO-2009070164-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA (US) 2009-06-04 WO claimed
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2008-05-29 US claimed
US-5976523-A PIPERIDINE- OR PIPERAZINE-SUBSTITUTED PYRROLOPYRIMIDINES MITSUI PHARMACEUTICALS, INC. (JP) 1999-11-02 US claimed
EP-0743066-A2 Wound-healing agent MITSUI PHARMACEUTICALS, INC. (JP) 1996-11-20 EP claimed
US-20230302000-A1 COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS Progenicyte Therapeutics, Inc. (US) 2023-09-28 US disclosed
US-20210046079-A1 COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2021-02-18 US disclosed
US-20200246334-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2020-08-06 US disclosed
US-20190167674-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2019-06-06 US disclosed
US-20180092913-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2018-04-05 US disclosed
EP-2326330-B1 COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS UNIV CENTRAL FLORIDA RES FOUND (US) 2015-01-07 EP disclosed
US-8791128-B2 Compositions for treating or delaying the onset of hair loss UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2014-07-29 US disclosed
WO-2010033576-A1 COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2010-03-25 WO disclosed
WO-2009070164-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES UNIVERSITY OF CENTRAL FLORIDA (US) 2009-06-04 WO disclosed
US-20090087462-A1 Use of pyrimidine derivatives for cosmetic purposes TREMBLEY MARCELLA 2009-04-02 US disclosed
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. 2008-05-29 US disclosed
EP-1890673-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSMIP Assets B.V. (NL) 2008-02-27 EP disclosed
WO-2006133876-A1 USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES DSM IP ASSETS B.V. (NL) 2006-12-21 WO disclosed
US-5976523-A PIPERIDINE- OR PIPERAZINE-SUBSTITUTED PYRROLOPYRIMIDINES MITSUI PHARMACEUTICALS, INC. (JP) 1999-11-02 US disclosed
EP-0743066-A2 Wound-healing agent MITSUI PHARMACEUTICALS, INC. (JP) 1996-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080124306-A1 Vigor Enhancement Via Administration of Pyrimidine Derivatives TYMP, SLC18A3, SLC18A2 POLB 943/4885SMN1; SMN2 205/4885TSHR 1811/4885
US-20190167674-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 POLB 943/4885SMN1; SMN2 205/4885TSHR 1811/4885
US-20210046079-A1 COMBINATION THERAPY TO IMPROVE BRAIN FUNCTION OR PROMOTE NEUROGENESIS FOR TREATING NEURODEGENERATIVE CONDITIONS PSEN1, PSEN2, NES POLB 3126/4885SMN1; SMN2 80/4885TSHR 3594/4885
US-20090087462-A1 Use of pyrimidine derivatives for cosmetic purposes TYMP, TYMS, UNG POLB 19/4885SMN1; SMN2 3270/4885TSHR 3157/4885
US-20180092913-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 POLB 943/4885SMN1; SMN2 205/4885TSHR 1811/4885
US-20230302000-A1 COMBINATION DRUG TREATMENT TO INCREASE NEUROGENESIS FOR NEUROLOGICAL DISORDERS NES, PSEN1, PSEN2 POLB 3750/4885SMN1; SMN2 78/4885TSHR 3492/4885
US-20200246334-A1 VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES TYMP, SLC18A3, SLC18A2 POLB 943/4885SMN1; SMN2 205/4885TSHR 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.